Knight Therapeutics (TSE:GUD) Sets New 12-Month High – Time to Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high during trading on Monday . The company traded as high as C$7.32 and last traded at C$7.32, with a volume of 3480 shares changing hands. The stock had previously closed at C$7.08.

Knight Therapeutics Stock Up 1.5%

The company has a debt-to-equity ratio of 10.15, a quick ratio of 1.79 and a current ratio of 2.39. The stock’s 50-day moving average price is C$6.26 and its two-hundred day moving average price is C$6.08. The stock has a market capitalization of C$726.44 million, a PE ratio of -148.20, a P/E/G ratio of -1,013.50 and a beta of 0.15.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings results on Thursday, March 19th. The company reported C$0.09 earnings per share (EPS) for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%. The company had revenue of C$133.20 million during the quarter. As a group, analysts expect that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.